Study guide: South African HIV ART Guidelines

Course Outline

  1. ART Goals and Eligibility
  2. When to Defer ART
  3. Baseline ART Evaluation
  4. Renal Function and Cotrimoxazole
  5. TB Preventive Therapy
  6. Dolutegravir Use and Interactions
  7. ART Regimens and Re-engagement
  8. Family Planning During ART
  9. TB Treatment Drug Interactions
  10. HIV and Active TB Co-treatment
  11. Enhanced Adherence Counselling
  12. Mental Health Assessment and Support
  13. Administration of Antiretroviral Drugs
  14. Disclosure of HIV Status to Children
  15. Adverse Drug Reaction Reporting

1. ART Goals and Eligibility

★ Must-know

  • The principal goal of ART is to attain and maintain viral suppression, preventing new HIV infections, increasing life expectancy, decreasing morbidity and mortality, and improving quality of life.

📌 All people living with HIV are eligible for ART regardless of age, CD4 count, or clinical stage.

📌 In the absence of contraindications, ART should start within 7 days and, if possible, on the same day.

Further detail

📌 Pregnant women, infants, children under 5 years, and clients with advanced HIV disease should be prioritised for rapid ART initiation.

2. When to Defer ART

★ Must-know

📌 For symptomatic clients with cough, night sweats, fever, or recent weight loss, investigate for TB before ART; if TB is excluded, start ART and consider TB preventive therapy after excluding its contraindications, but if TB is diagnosed, start TB treatment and defer ART according to infection site and CD4 count.

📌 For non-neurological drug-sensitive TB, start ART within 2 weeks of TB treatment when symptoms are improving and treatment is tolerated if CD4 is below 50 cells/µL; if CD4 is at least 50 cells/µL, start ART 8 weeks after TB treatment begins.

Further detail

  • For pregnant or breastfeeding women with non-neurological TB, start ART within 2 weeks of TB treatment when symptoms are improving and treatment is tolerated; defer ART for 4–6 weeks if meningitis symptoms are present.

  • For drug-resistant TB at a non-neurological site, start ART after 2 weeks of TB treatment when symptoms are improving and treatment is tolerated.

  • For drug-sensitive or drug-resistant TB at a neurological site, defer ART until 4–8 weeks after TB treatment starts.

  • An asymptomatic client with a positive serum cryptococcal antigen and a negative lumbar puncture for cryptococcal meningitis does not need an ART delay and may start ART immediately.

  • For confirmed cryptococcal meningitis, defer ART until 4–6 weeks of antifungal treatment have been completed.

  • For other acute illnesses such as Pneumocystis jirovecii pneumonia or bacterial pneumonia, defer ART for 1–2 weeks after treatment for the infection begins.

  • With clinical signs of liver disease, confirm liver injury using ALT and total bilirubin; ALT above 120 IU/L with hepatitis symptoms and/or total serum bilirubin above 40 µmol/L is significant and requires investigation and management of possible causes.

  • Clients already taking ART should not have treatment interrupted when one of the listed acute conditions is diagnosed.

3. Baseline ART Evaluation

★ Must-know

  • Baseline clinical and laboratory investigations should be performed before ART, but results need not be available to start ART on the same day if there is no clinical evidence of TB, meningitis, or renal disease.

Further detail

  • Clients and caregivers of paediatric clients should receive counselling on medication administration, side-effect monitoring, and adherence challenges.

  • Baseline evaluation includes a thorough history and clinical examination, assessment for danger signs, nutritional assessment, TB screening, meningitis symptoms, mental health and substance use, chronic diseases, pregnancy and fertility intentions, STIs, child neurodevelopment, and WHO clinical stage.

  • For adults, a BMI below 18.5 kg/m² indicates underweight, 18.5 to below 25 indicates normal weight, at least 25 to below 30 indicates overweight, and at least 30 indicates obesity.

📌 Women with a mid-upper arm circumference below 23 cm require additional nutritional support or referral.

  • Routine TB screening at HIV care enrolment includes symptom screening and clinical examination, with MTB/Rif Ultra testing at enrolment regardless of TB symptoms; pregnant women receive symptom screening, examination, and routine MTB/Rif Ultra testing at their first antenatal visit.

📌 For symptomatic people living with HIV admitted to hospital, add urine LAM, chest X-ray if clinically indicated, and investigations for extrapulmonary TB if clinically indicated to MTB/Rif Ultra testing.

📌 For symptomatic outpatients, add urine LAM to MTB/Rif Ultra testing if CD4 is below 200 within the last 6 months, advanced HIV disease is present, or there is current serious illness; obtain chest X-ray if clinically indicated.

  • Adherence counselling should: explain HIV, ART, and viral suppression, build practical adherence skills, identify future adherence risks, develop an individual plan with treatment milestones, including an undetectable viral load

  • Meningitis screening includes headache, confusion, or visual disturbance; cryptococcal meningitis may present with recurrent headache, fever, neck stiffness, or coma, and suspected cases require referral for lumbar puncture.

📌 HIV-positive women should be screened for cervical cancer at diagnosis and every 3 years if the screening test is negative; screening may be performed up to 20 weeks of gestation.

📌 If hepatitis B surface antigen is positive, use caution when stopping TDF-containing regimens to prevent hepatitis flares.

4. Renal Function and Cotrimoxazole

★ Must-know

📐 Formula - For ages 10 to under 16 years, eGFR is calculated using height in cm×40serum creatinine in \mumol/L\frac{\text{height in cm} \times 40}{\text{serum creatinine in \mu{}mol/L}}, and TDF use is acceptable above 80 mL/min/1.73 m².

  • For adults and adolescents aged at least 16 years, TDF use is acceptable when eGFR calculated by the MDRD equation is above 50 mL/min/1.73 m².

📌 Cotrimoxazole preventive therapy is indicated for all HIV-positive infants under 1 year, regardless of CD4 percentage or clinical stage.

Further detail

📌 For pregnant women, TDF use is acceptable when absolute serum creatinine is below 85 µmol/L.

  • Dolutegravir may raise serum creatinine by less than 15% early in treatment through reduced tubular secretion without affecting glomerular filtration; a stable increase is not an indication to stop DTG.

📌 For HIV-positive children aged 1–5 years, start cotrimoxazole if CD4 is at most 25% or WHO stage is 2, 3, or 4, and continue until CD4 exceeds 25% regardless of clinical stage.

📌 For HIV-positive adults and children older than 5 years, start cotrimoxazole if CD4 is at most 200 cells/µL or WHO stage is 2, 3, or 4, and stop when CD4 exceeds 200 cells/µL regardless of clinical stage.

5. TB Preventive Therapy

★ Must-know

  • Before starting TB preventive therapy, rule out active TB clinically and by testing; if a client is asymptomatic, preventive therapy need not wait for outstanding GeneXpert results, and TB preventive therapy and ART may start on the same day.

  • For non-pregnant adults or adolescents aged at least 15 years, TB preventive therapy is isoniazid 300 mg daily for 12 months with pyridoxine 25 mg daily, excluding active liver disease, alcohol abuse, or known isoniazid hypersensitivity.

  • For children younger than 15 years living with HIV, including neonates with significant TB exposure, isoniazid is 10 mg/kg/day for 6 months, with a maximum of 300 mg daily, plus daily pyridoxine.

Further detail

  • A tuberculin skin test is not required before starting TB preventive therapy.

  • In well children without TB symptoms, neither sputum testing nor chest X-ray is required before TB preventive therapy; attempt sputum testing in children able to expectorate, typically those over 25 kg.

  • A well child unable to expectorate should start TB preventive therapy even if chest X-ray or sputum testing is unavailable.

  • Weekly isoniazid and rifapentine for 3 months may be used at selected locations in eligible clients on DTG with viral load below 50 copies/mL in the previous 6 months, but it should not be used in new clients initiating a DTG regimen.

6. Dolutegravir Use and Interactions

★ Must-know

  • Dolutegravir is an integrase inhibitor that provides rapid viral suppression, has a high genetic barrier to resistance, minimal side effects and drug interactions, and is generally well tolerated.

  • The adult TLD fixed-dose combination contains tenofovir 300 mg, lamivudine 300 mg, and dolutegravir 50 mg and is prescribed from 30 kg and 10 years of age.

📌 With rifampicin-containing TB treatment, increase DTG to 50 mg every 12 hours; for clients taking TLD or ALD, add DTG 50 mg 12 hours after the fixed-dose combination.

Further detail

  • The paediatric ALD fixed-dose combination contains abacavir 600 mg, lamivudine 300 mg, and dolutegravir 50 mg and may be prescribed from 25 kg.

  • Dolutegravir 10 mg dispersible tablets are available for children from 3 kg and 4 weeks of age, while the 50 mg film-coated tablet is equivalent to 30 mg of dispersible tablets.

  • For children weighing at least 20 kg and for adults and adolescents, the standard DTG dose is 50 mg daily.

  • Calcium and iron supplements may be taken with DTG at the same time if taken with food, but calcium and iron supplements must be separated by at least 4 hours from each other.

  • Magnesium- or aluminium-containing antacids should be taken at least 2 hours after or 6 hours before DTG, regardless of food.

  • If possible, avoid coadministration of DTG with carbamazepine, phenobarbital, or phenytoin; alternatives include valproate, lamotrigine, levetiracetam, and topiramate, while valproate is contraindicated during pregnancy.

  • If no alternative anticonvulsant is suitable, double DTG to 50 mg every 12 hours with carbamazepine, phenytoin, or phenobarbital.

  • DTG increases metformin concentrations, so the maximum metformin dose is 500 mg every 12 hours.

  • DTG may cause mild, self-limiting insomnia, headache, central nervous system effects, and gastrointestinal effects; if insomnia develops, TLD should be taken in the morning.

  • The association between integrase inhibitors and weight gain is not considered causal; proposed explanations include lower metabolic toxicity than older regimens, return to health, and an obesogenic environment, and weight gain alone is not a reason to switch from a DTG regimen.

7. ART Regimens and Re-engagement

★ Must-know

📌 TLD1 describes clients on a DTG-containing regimen who have never failed a previous regimen, whereas TLD2 describes clients on a DTG-containing regimen who have failed an earlier regimen.

Further detail

  • TLD may be used as first-line, second-line, and, with other medicines in certain cases, third-line ART.

📌 All ART clients not taking DTG should be evaluated for a switch to a DTG-containing regimen, including those on first- or second-line treatment.

  • Clients returning to care after more than 90 days who previously used TDF, TLD, or a protease-inhibitor regimen should restart a DTG-containing regimen; clients previously lost to follow-up on third-line therapy should restart their third-line regimen.

📌 For confirmed drug-sensitive TB at a non-neurological site, start ART within 2 weeks of TB treatment if CD4 is below 50 cells/µL and after 8 weeks if CD4 is at least 50 cells/µL.

8. Family Planning During ART

★ Must-know

  • Family planning and contraception should be discussed at every clinical interaction, with contraceptive options offered through integrated, patient-centred services and informed voluntary choice.

Further detail

  • Available contraceptive options include:

    • condoms
    • oral contraceptives
    • implants
    • injectables
    • intrauterine contraceptive devices
  • Dual contraception combines a hormonal method or intrauterine device to prevent pregnancy with a male or female condom to prevent STIs and HIV transmission.

📌 A woman who wishes to become pregnant should be counselled to establish ART, attain viral suppression, and have no current opportunistic infections before trying to conceive.

9. TB Treatment Drug Interactions

★ Must-know

  • Rifampicin-containing TB treatment has significant interactions with all paediatric ART regimens and with adult or adolescent regimens containing DTG.

📌 Adults, adolescents and children able to swallow whole LPV/r tablets should receive double-dose LPV/r tablets with rifampicin; the tablets must not be crushed, broken or chewed.

  • For clients taking LPV/r solution or pellets, or 4-in-1 ABC/3TC/LPV/r, maintain the standard LPV/r dose and add ritonavir powder twice daily; if powder is unavailable, consult an expert for an alternative.

📌 Adults and adolescents taking rifampicin should increase dolutegravir dosing to 50 mg every 12 hours.

Further detail

📌 Rifampicin cannot be given with atazanavir/ritonavir or darunavir/ritonavir.

  • Drug interactions can lower antiretroviral concentrations, causing elevated HIV viral load and drug resistance through viral replication at subtherapeutic drug concentrations.

  • If a client cannot tolerate doubled LPV/r doses, consult a helpline.

  • Ritonavir 100 mg tablets must not be crushed, broken or chewed.

  • For a client taking TLD, give an additional 50 mg of dolutegravir 12 hours after the TLD dose.

  • Continue boosting the ART regimen until 2 weeks after rifampicin is stopped.

  • Ritonavir powder has a shelf life of 36 months.

10. HIV and Active TB Co-treatment

★ Must-know

  • Children and adolescents who are not yet on ART when TB treatment starts should initiate ART with a dolutegravir-containing regimen, with dolutegravir boosting as indicated.

  • Adults who are not yet on ART when TB treatment starts should initiate either a dolutegravir-containing regimen with dolutegravir boosting, or an efavirenz-containing regimen if they are ART-treatment-naive.

  • Clients already taking a dolutegravir-containing regimen when TB treatment starts should continue that regimen during TB treatment, with dolutegravir boosting as indicated.

  • Clients already virally suppressed on an efavirenz-containing regimen when TB treatment starts should continue that regimen until 2 weeks after TB treatment is completed, after which efavirenz can be switched to dolutegravir.

  • Results of TB investigations and viral load should be reviewed within 5–7 days, or sooner if possible.

📌 A patient diagnosed with TB and/or with viral load ≥50 copies/mL returns to regular clinician-managed care and is reassessed for RPCS enrolment after TB treatment is completed and/or viral load is again <50 copies/mL.

📌 A patient who is not diagnosed with TB and whose viral load was suppressed continues in RPCS.

Further detail

  • Efavirenz has no significant drug interaction with rifampicin and is taken once daily, which supports adherence.

  • Rifampicin treatment can increase pill burden, reduce ART drug concentrations through significant drug interactions, and cause overlapping toxicities such as hepatic toxicity.

📌 Clinicians should provide integrated TB and ART management at clinical consultation visits because separate care increases visits and the risk of disengagement.

  • In the RPCS TB schedule, the facility dispenses the first 3 months of ART supply and RPCS provides the next 3 months; where facility stock shortage is a concern, the facility may provide 2 months and RPCS the next 4 months.

📌 When a facility has an effective results-management and recall system, it may recall only clients with a positive TB diagnosis and/or viral load ≥50 copies/mL; otherwise, the client returns within 5–7 days for combined review of TB and viral-load results.

  • Clients taking rifampicin-containing TB treatment require dolutegravir boosting; adults and adolescents should take dolutegravir 50 mg every 12 hours, and boosting continues until 2 weeks after TB treatment ends.

Memory Hook

Starting ART during TB treatment differs from continuing an existing ART regimen.

11. Enhanced Adherence Counselling

★ Must-know

  • Enhanced adherence counselling has two sessions: an initial session for patients struggling with adherence and a second session for persistently non-adherent patients.

  • In the initial session, explain its purpose, identify possible reasons for abnormal assessment results, address adherence barriers and strategies, and update or develop an adherence plan with the patient.

Further detail

  • Initial-session assessment includes mental-health screening, checking the patient's understanding of their regimen and when each medicine is taken, reviewing prior treatment education, and explaining that incorrect medication use is the most common reason for an abnormal result.

📌 Counselling should explain that patients should take treatment even if they cannot control their alcohol use, and should plan with a clinician to continue treatment if they use traditional medicines that may interfere with it.

  • Adherence strategies include:

    • A treatment buddy
    • A phone alarm
    • Support from a family member
    • Pill counts
    • A calendar or pillbox
    • Linking medication to meals or daily routines
    • Accessible medication storage
    • Carrying spare medication for work
    • Modified directly observed therapy
  • The initial session should explain future adherence and effectiveness assessments, such as a further viral load in 3 months for HIV, blood pressure at every visit for the next 3 months for hypertension, and HbA1c in 3 months for diabetes.

Memory Hook

Session 1 moves from assessment to treatment flexibility, lived experience, adherence strategies, and the pathway ahead.

12. Mental Health Assessment and Support

★ Must-know

  • Basic screening assesses:
    • Appearance
    • Mood
    • Thoughts
    • Cognition

📌 Negative thoughts can suggest depression, while unusual thoughts or experiences such as hearing voices or seeing visions can raise suspicion of psychosis.

📌 Direct referral for psychiatric support is indicated for intense sadness, risk of harm to self or others, or hearing or seeing things that others do not.

Further detail

  • When a mental-health disorder is suspected, assess the main problem, its duration, effects on daily functioning, and whether the clinic can manage it; refer to a psychiatric nurse or service if further assessment or treatment is unavailable at the clinic.

  • The WHO-recommended SRQ20 can help identify mental-health disorders.

13. Administration of Antiretroviral Drugs

★ Must-know

  • Abacavir should be stopped permanently if a hypersensitivity reaction has occurred.

  • Zidovudine should be avoided or used cautiously in neonates or children with haemoglobin below 8 g/dL because it can suppress bone marrow.

  • Tenofovir may be prescribed for adolescents aged at least 10 years and weighing at least 35 kg after renal function is checked, with creatinine and eGFR assessed at months 3 and 10 and every 12 months thereafter.

  • Dolutegravir dispersible and film-coated tablets are not bioequivalent: 30 mg of dispersible tablet corresponds to 50 mg of film-coated tablet.

Further detail

📌 Dolutegravir and iron supplements may be taken together if taken with food, because iron decreases dolutegravir concentrations when both are taken together on an empty stomach.

  • Lopinavir/ritonavir tablets must be swallowed whole, while capsules may be opened and mixed with a small amount of soft food or liquid for immediate ingestion.

14. Disclosure of HIV Status to Children

★ Must-know

  • Full HIV-status disclosure should ideally occur between ages 10 and 14 for a child with normal cognition and maturity, before sexual debut.

  • Disclosure is ideally gradual over many years, progressing from partial disclosure to full disclosure, post-disclosure, and ongoing support.

Further detail

  • During partial disclosure at ages 5–9, the child learns about illness and why medicine is needed but is not yet told that the illness is HIV.

📌 Before full disclosure, assess the adolescent's cognitive and emotional maturity, prepare the parent or caregiver, obtain consent to disclose the adolescent's and caregiver's HIV status, and find out what the adolescent already knows.

  • After full disclosure, repeat key information during follow-up, assess mental health and coping, discuss disclosure to friends or partners, and address sexual health, condom use, family planning, and daily treatment.

15. Adverse Drug Reaction Reporting

★ Must-know

📌 Healthcare professionals and consumers are urged to report all adverse drug reactions, adverse events following immunisation, and product-quality concerns to the SAHPRA pharmacovigilance office.

Further detail

  • Reporting methods include:
    • Email to [email protected]
    • The WHO online e-reporting portal
    • The MedSafety smartphone application

Test yourself

Take a 40-question practice quiz on South African HIV ART Guidelines, with every answer explained.

1. Which outcome best captures the principal goal of antiretroviral therapy (ART)?

2. A person living with HIV has a high CD4 count and no advanced clinical symptoms; how should their eligibility for ART be assessed?

Take the quiz →

Study with flashcards

Memorize the key concepts of South African HIV ART Guidelines with 92 flashcards.

What is the principal goal of ART?

To attain and maintain viral suppression.

What does viral suppression through ART help prevent?

New HIV infections.

How does ART affect life expectancy?

It increases life expectancy.

See the flashcards →

Related classes

Make your own study guides

Upload your class notes and Revizly writes a study guide, a quiz and flashcards in about a minute.

Study guide maker